Skip to main content
Non-financial boards have been closed.

Non-financial boards have been closed but will continue to be accessible in read-only form. If you're disappointed, we understand. Thank you for being an active participant in this community. We have more community features in development that we look forward to sharing soon. | The Motley Fool Community
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
If Civica can do what it claims, and even get close on their proposed price, that will crash the marketplace for fast-acting insulin.

Basal products such as Lantus, Basaglar, etc will take longer. Lantus is no longer protected by patents, but the production requirements are, as yet, not really known except to the companies.

Trulicity, etc would be much longer still because they do fill a niche fast-acting insulin can not. And this class of drugs would have significant production costs even if there were no patents.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.